Prolactinoma – Comprehensive Medical Guide

Overview

Prolactinoma is a benign (non‑cancerous) tumor that arises from the lactotroph cells of the anterior pituitary gland and secretes excess prolactin. Prolactin is a hormone that stimulates breast milk production and has many other regulatory functions. When a prolactinoma produces too much prolactin, it can disrupt the normal hormonal balance and cause a range of symptoms.

Who it affects

• Gender: Women are diagnosed more often (≈ 8–10 per 100,000 women per year) because the hormonal effects (amenorrhea, infertility, galactorrhea) are more noticeable. Men are less frequently diagnosed, but when they are, tumors tend to be larger.
• Age: Most cases are identified between 20 and 50 years of age. Small “micro‑prolactinomas” (<10 mm) are common in younger adults, while larger “macro‑prolactinomas” (≥10 mm) are more frequent in middle‑aged men.
• Geography/Ethnicity: No strong ethnic predilection has been documented; prevalence appears similar worldwide.

Prevalence

• Overall prevalence of clinically significant prolactin‑secreting adenomas is about 0.1 % of the general population (≈ 100 per 100,000) (Mayo Clinic, 2023).
• Incidental pituitary microadenomas are found on MRI in up to 10 % of healthy adults, but only a minority secrete excess prolactin.

Symptoms

Symptoms stem from two mechanisms: (1) hyperprolactinemia (excess hormone) and (2) mass effect of the tumor compressing nearby structures.

Symptoms caused by excess prolactin

• Women
  • Amenorrhea or oligomenorrhea – absent or infrequent menstrual periods.
  • Infertility – difficulty conceiving due to disrupted ovulation.
  • Galactorrhea – milky discharge from one or both breasts unrelated to pregnancy or nursing.
  • Decreased libido and vaginal dryness – due to reduced estrogen.
  • Headaches – often mild, worsened by hormonal fluctuations.
• Men
  • Erectile dysfunction and reduced libido.
  • Gynecomastia – breast tissue enlargement.
  • Infertility – low testosterone and impaired spermatogenesis.
  • Galactorrhea (rare).
• Both sexes
  • Hot flashes, mood swings, or depression – related to hormonal imbalance.
  • Fatigue and general malaise.

Symptoms caused by tumor size (mass effect)

• Headache – often dull, localized behind the eyes or in the frontal region.
• Visual field defects – classically bitemporal hemianopsia (loss of vision on the outer halves of both visual fields) when the tumor compresses the optic chiasm.
• Loss of peripheral vision – may be subtle at first.
• Hormonal deficiencies – large tumors can impair other pituitary hormones, causing fatigue, low blood pressure, or hypothyroidism.

Causes and Risk Factors

Primary cause

The exact trigger for a prolactinoma is unknown, but it is believed to arise from genetic and cellular changes that cause lactotroph cells to proliferate and secrete prolactin autonomously.

Genetic factors

• Multiple endocrine neoplasia type 1 (MEN‑1) – a rare inherited syndrome that includes pituitary adenomas in up to 40 % of carriers.
• Familial isolated pituitary adenomas (FIPA) – mutations in the AIP gene increase risk, especially for larger tumors in men.

Other risk factors

• Female sex (higher detection due to symptoms).
• Age 20‑50 years.
• History of head trauma or radiation to the brain (very rare).
• Use of certain medications that raise prolactin (e.g., antipsychotics, dopamine antagonists). Though drug‑induced hyperprolactinemia is not a true prolactinoma, it can mimic the condition and sometimes unmask a pre‑existing microadenoma.

Diagnosis

A stepwise approach is used to confirm the presence of a prolactinoma, assess its size, and rule out other causes of hyperprolactinemia.

1. Clinical evaluation

• Detailed medical history focusing on menstrual changes, sexual function, galactorrhea, headaches, and visual disturbances.
• Physical exam including breast examination (women), testicular exam (men), and visual field testing.

2. Laboratory tests

• Serum prolactin level – A single measurement > 20 ng/mL in women or > 15 ng/mL in men is abnormal. Levels > 200 ng/mL almost always indicate a prolactin‑secreting tumor.
• Assess other pituitary hormones (TSH, free T4, cortisol, ACTH, LH/FSH, growth hormone) to detect hypopituitarism.
• Rule out secondary causes: thyroid‑stimulating hormone (TSH) to exclude hypothyroidism, renal function, liver function, and pregnancy test in women.

3. Imaging

• Magnetic Resonance Imaging (MRI) of the sellar region – Preferred test; detects micro‑ (<10 mm) and macro‑prolactinomas with > 90 % sensitivity.
• If MRI is contraindicated, a CT scan can provide limited information.

4. Visual field testing

Standard automated perimetry (e.g., Humphrey visual field) is performed when a macroadenoma is suspected, especially if the patient reports visual changes.

5. Differential diagnosis

Other conditions that can cause elevated prolactin include:

• Physiologic states: pregnancy, breastfeeding, stress.
• Medications: antipsychotics, antidepressants, anti‑emetics.
• Hypothyroidism (elevated TRH stimulates prolactin).
• Chest wall irritation (e.g., shingles, surgery).

Treatment Options

Therapy is tailored to tumor size, symptom severity, and patient preference. The primary goals are to normalize prolactin levels, shrink tumor size, restore fertility, and preserve vision.

1. Medications (first‑line)

• Dopamine agonists (DA) – mimic dopamine’s inhibitory effect on prolactin secretion.
  • Cabergoline (Dostinex) – preferred because of high efficacy (normalizes prolactin in > 90 % of patients) and low side‑effect profile. Typical dose: 0.25–1 mg twice weekly.
  • Bromocriptine (Parlodel) – older agent; effective but requires daily dosing and more gastrointestinal side effects.
  • Common side effects: nausea, dizziness, orthostatic hypotension, rare impulse‑control disorders.
• Medication choice is often guided by tolerance, size of tumor, and pregnancy plans.

2. Surgical removal

• Indicated when:
  • DA therapy is contraindicated or not tolerated.
  • Tumor fails to shrink or prolactin remains elevated despite maximal medical therapy.
  • Acute visual loss from compression.
• Transsphenoidal endoscopic surgery is the standard approach, with cure rates of 70‑90 % for microadenomas and 50‑70 % for macroadenomas.
• Potential complications: CSF leak, sinus infection, temporary hormonal deficiencies.

3. Radiation therapy

• Reserved for residual or recurrent tumor after surgery/DA failure.
• Conventional fractionated radiotherapy or stereotactic radiosurgery (Gamma Knife) can achieve tumor control in 80‑90 % of cases, but prolactin normalization may take years.
• Long‑term risk of hypopituitarism (10‑30 %).

4. Lifestyle & supportive measures

• Stop medications that raise prolactin (after physician discussion).
• Maintain a healthy weight – obesity can exacerbate hormonal imbalance.
• Stress‑management techniques (yoga, mindfulness) may help reduce headache frequency.

Living with Prolactinoma

Medication adherence

Take dopamine agonists exactly as prescribed. Missing doses can cause rebound hyperprolactinemia and return of symptoms. Use pill organizers or smartphone reminders.

Monitoring schedule

• Serum prolactin: every 3‑6 months until stable, then annually.
• MRI: baseline, then at 6‑12 months after starting therapy; later imaging every 2‑3 years if tumor is stable.
• Visual fields: annually for macroadenomas or if symptoms develop.

Fertility planning

Both men and women often regain fertility after prolactin normalizes. Cabergoline is considered safe in pregnancy once conception is confirmed; discuss timing with an OB‑GYN and endocrinologist.

Managing side effects

• Take DA with food to reduce nausea.
• Rise slowly from sitting/lying positions to avoid dizziness.
• Report any new compulsive behaviors (e.g., gambling) to your doctor—rare but documented.

Emotional health

Hyperprolactinemia can affect mood. Consider counseling, support groups, or cognitive‑behavioral therapy if anxiety or depression arise.

Prevention

Because most prolactinomas are sporadic and not linked to modifiable lifestyle factors, primary prevention is limited. However, you can reduce the risk of secondary hyperprolactinemia and early tumor detection by:

• Avoiding long‑term use of prolactin‑raising drugs unless medically required.
• Promptly treating hypothyroidism, as low thyroid hormone can stimulate prolactin release.
• Seeking medical evaluation for unexplained menstrual irregularities, infertility, or persistent galactorrhea.

Complications

If left untreated, prolactinoma can lead to significant health problems.

• Infertility – persistent anovulation in women, low sperm count in men.
• Osteoporosis – chronic hypogonadism reduces estrogen/testosterone, leading to bone loss.
• Visual loss – irreversible optic nerve damage if compression is prolonged.
• Pituitary apoplexy – sudden hemorrhage into the tumor causing severe headache, visual impairment, and hormonal crisis (medical emergency).
• Psychiatric issues – depression, anxiety, decreased quality of life.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Prolactinoma.” 2023; CDC. “Hormone‑related disorders.” 2022; National Institutes of Health (NIH) – Endocrine Society Clinical Practice Guidelines, 2021; World Health Organization (WHO) – Tumor classification, 2022; Cleveland Clinic. “Pituitary Tumors.” 2023; peer‑reviewed articles in Journal of Clinical Endocrinology & Metabolism and Science Translational Medicine.